Systematic Financial Management LP acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 14,881 shares of the biopharmaceutical company’s stock, valued at approximately $1,206,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. lifted its position in Gilead Sciences by 9.9% during the third quarter. Pacer Advisors Inc. now owns 84,702 shares of the biopharmaceutical company’s stock valued at $6,863,000 after purchasing an additional 7,617 shares during the last quarter. Skba Capital Management LLC lifted its position in Gilead Sciences by 13.8% during the third quarter. Skba Capital Management LLC now owns 162,150 shares of the biopharmaceutical company’s stock valued at $13,137,000 after purchasing an additional 19,650 shares during the last quarter. Point View Wealth Management Inc. lifted its position in Gilead Sciences by 16.7% during the third quarter. Point View Wealth Management Inc. now owns 11,047 shares of the biopharmaceutical company’s stock valued at $895,000 after purchasing an additional 1,582 shares during the last quarter. Dowling & Yahnke LLC lifted its position in Gilead Sciences by 4.8% during the third quarter. Dowling & Yahnke LLC now owns 47,193 shares of the biopharmaceutical company’s stock valued at $3,824,000 after purchasing an additional 2,151 shares during the last quarter. Finally, AE Wealth Management LLC bought a new stake in Gilead Sciences during the third quarter valued at approximately $259,000. Institutional investors own 75.95% of the company’s stock.
Several research analysts have commented on the stock. Berenberg Bank set a $96.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reissued a “buy” rating and set a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. Finally, Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target on the stock in a research note on Friday, October 13th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $85.53.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $80.98 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a market cap of $105,781.67, a price-to-earnings ratio of 9.22, a P/E/G ratio of -1.76 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period in the previous year, the firm earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.57%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.
TRADEMARK VIOLATION WARNING: “Systematic Financial Management LP Acquires Shares of 14,881 Gilead Sciences, Inc. (GILD)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3148758/systematic-financial-management-lp-acquires-shares-of-14881-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.